CN114295842A - A kind of adiponectin detection kit and preparation method thereof - Google Patents
A kind of adiponectin detection kit and preparation method thereof Download PDFInfo
- Publication number
- CN114295842A CN114295842A CN202111655950.4A CN202111655950A CN114295842A CN 114295842 A CN114295842 A CN 114295842A CN 202111655950 A CN202111655950 A CN 202111655950A CN 114295842 A CN114295842 A CN 114295842A
- Authority
- CN
- China
- Prior art keywords
- reagent
- adiponectin
- detection kit
- preservative
- buffer solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000011690 Adiponectin Human genes 0.000 title claims abstract description 52
- 108010076365 Adiponectin Proteins 0.000 title claims abstract description 52
- 238000001514 detection method Methods 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 92
- 239000004816 latex Substances 0.000 claims abstract description 51
- 229920000126 latex Polymers 0.000 claims abstract description 51
- 239000002245 particle Substances 0.000 claims abstract description 33
- 239000004359 castor oil Substances 0.000 claims abstract description 31
- 235000019438 castor oil Nutrition 0.000 claims abstract description 31
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 31
- 239000004094 surface-active agent Substances 0.000 claims abstract description 28
- 229920002366 Tetronic® 1307 Polymers 0.000 claims abstract description 27
- 239000000872 buffer Substances 0.000 claims abstract description 24
- 239000003755 preservative agent Substances 0.000 claims abstract description 24
- 230000002335 preservative effect Effects 0.000 claims abstract description 21
- 239000003381 stabilizer Substances 0.000 claims abstract description 10
- 239000003792 electrolyte Substances 0.000 claims abstract description 9
- 239000003223 protective agent Substances 0.000 claims abstract description 9
- 239000007853 buffer solution Substances 0.000 claims abstract 9
- 239000000126 substance Substances 0.000 claims description 35
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 33
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 28
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 27
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 27
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 23
- 239000007995 HEPES buffer Substances 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 14
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 14
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 14
- 239000011780 sodium chloride Substances 0.000 claims description 14
- 239000008118 PEG 6000 Substances 0.000 claims description 13
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 13
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000004005 microsphere Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000011534 incubation Methods 0.000 claims description 8
- 238000002844 melting Methods 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 229920002359 Tetronic® Polymers 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 239000005018 casein Substances 0.000 claims description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- -1 melting promoter Substances 0.000 claims 1
- 239000008055 phosphate buffer solution Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 12
- 238000001179 sorption measurement Methods 0.000 abstract description 5
- 150000002632 lipids Chemical class 0.000 abstract description 3
- 239000003623 enhancer Substances 0.000 abstract description 2
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 abstract 1
- 210000001268 chyle Anatomy 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 238000002835 absorbance Methods 0.000 description 9
- 239000007987 MES buffer Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000002452 interceptive effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical compound C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000001132 ultrasonic dispersion Methods 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明公开了一种脂联素检测试剂盒及其制备方法,该脂联素检测试剂盒包括R1试剂和R2试剂;R1试剂包括以下成分:缓冲液、电解质、促融剂、表面活性剂和防腐剂;R2试剂包括以下成分:抗脂联素单抗包被胶乳颗粒、缓冲液、保护剂、稳定剂、防腐剂和表面活性剂;其中,表面活性剂选自Tetronic 1307、蓖麻油聚氧乙烯醚中的一种或两种。本发明的试剂盒通过采用新的表面活性剂组合与试剂盒中的其他成分配合,不仅增强了试剂对特殊样本如乳糜类和脂浊类样本的抗干扰能力,减小非特异性吸附的干扰,提升样本测试的准确性,还增强了胶乳试剂的重复性和稳定性。
The invention discloses an adiponectin detection kit and a preparation method thereof. The adiponectin detection kit includes R1 reagent and R2 reagent; the R1 reagent includes the following components: buffer solution, electrolyte, fusion enhancer, surfactant and Preservative; R2 reagent includes the following components: anti-adiponectin monoclonal antibody-coated latex particles, buffer, protective agent, stabilizer, preservative and surfactant; wherein, the surfactant is selected from Tetronic 1307, castor oil polyoxygen One or both of vinyl ethers. The kit of the present invention not only enhances the anti-interference ability of the reagent for special samples such as chyle and lipid turbidity samples, but also reduces the interference of non-specific adsorption by using a new combination of surfactants to cooperate with other components in the kit. Improve the accuracy of sample testing, but also enhance the repeatability and stability of latex reagents.
Description
技术领域technical field
本发明涉及体外诊断试剂领域,尤其涉及一种脂联素检测试剂盒及其制备方法。The invention relates to the field of in vitro diagnostic reagents, in particular to an adiponectin detection kit and a preparation method thereof.
背景技术Background technique
脂联素(ADPN),是脂肪细胞分泌的一种内源性生物活性多肽和蛋白,能在血浆中稳定存在,约占血浆蛋白的0.01%。最早脂联素是在人体皮下脂肪组织、血浆和鼠科动物的脂肪细胞中被发现。Adiponectin (ADPN), an endogenous biologically active polypeptide and protein secreted by adipocytes, can exist stably in plasma, accounting for about 0.01% of plasma protein. The earliest adiponectin was found in human subcutaneous adipose tissue, plasma and murine adipocytes.
随着对脂联素的研究发现,脂联素是一种胰岛素增敏激素(An Insulin-sensitizing Hormone),能改善胰岛素抗性(Insulin resistance)和动脉硬化;脂联素水平能预示II型糖尿病和冠心病的发展,并在临床试验表现出与肥胖、糖尿病、胰岛素抵抗、动脉粥样和炎症都有一定相关性。因此,检测血中脂联素水平对这些疾病的诊断和预后均有重要意义。With the study of adiponectin, it was found that adiponectin is an insulin-sensitizing hormone (An Insulin-sensitizing Hormone), which can improve insulin resistance (Insulin resistance) and arteriosclerosis; Adiponectin level can predict type II diabetes and the development of coronary heart disease, and has been shown in clinical trials to be associated with obesity, diabetes, insulin resistance, atherosclerosis and inflammation. Therefore, the detection of blood adiponectin levels is of great significance for the diagnosis and prognosis of these diseases.
目前,测定脂联素的方法主要使用化学发光免疫分析法(CLIA)、酶联免疫吸附法(ELISA)和胶乳增强免疫比浊法。其中,化学发光法灵敏度较高,但需要专门的仪器,价格昂贵;酶联免疫法操作过程极为繁琐和复杂,检测时间长,重复性较差。胶乳增强免疫比浊法是利用一定粒径胶乳颗粒的表面交联单克隆或多克隆抗与抗原结合后,来检测抗原的浓度;现有的胶乳增强免疫比浊法的灵敏度高,但抗干扰性差,低值区重复性差,且制备工艺复杂,耗费人力物力。At present, the methods for the determination of adiponectin mainly use chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA) and latex-enhanced immunoturbidimetry. Among them, the chemiluminescence method has high sensitivity, but requires special equipment and is expensive; the ELISA method is extremely cumbersome and complicated, with long detection time and poor repeatability. The latex-enhanced immune turbidimetric method is to use the surface cross-linked monoclonal or polyclonal antibody of a certain size of latex particles to combine with the antigen to detect the concentration of the antigen; the existing latex-enhanced immune turbidimetric method has high sensitivity, but anti-interference The performance is poor, the repeatability in the low value area is poor, and the preparation process is complicated, which consumes manpower and material resources.
因此,现有技术有待进一步改进。Therefore, the existing technology needs to be further improved.
发明内容SUMMARY OF THE INVENTION
针对上述问题,本发明提供了一种新的抗干扰能力强、重复性好的脂联素检测试剂盒,并提供了该试剂盒的制备方法。In view of the above problems, the present invention provides a new adiponectin detection kit with strong anti-interference ability and good repeatability, and provides a preparation method of the kit.
为解决上述问题,本发明提供了以下技术方案:To solve the above problems, the present invention provides the following technical solutions:
第一方面,本发明提供一种脂联素检测试剂盒,其包括R1试剂和R2试剂;其中:In a first aspect, the present invention provides an adiponectin detection kit, which includes R1 reagent and R2 reagent; wherein:
R1试剂包括以下成分:缓冲液、电解质、促融剂、表面活性剂和防腐剂;The R1 reagent includes the following components: buffers, electrolytes, thawing agents, surfactants and preservatives;
R2试剂包括以下成分:抗脂联素单抗包被胶乳颗粒、缓冲液、保护剂、稳定剂、防腐剂和表面活性剂;The R2 reagent includes the following components: anti-adiponectin monoclonal antibody-coated latex particles, buffers, protective agents, stabilizers, preservatives, and surfactants;
其中,表面活性剂选自Tetronic 1307、蓖麻油聚氧乙烯醚、Tween-20、曲拉通-100和Brij-35中的一种或几种。Wherein, the surfactant is selected from one or more of Tetronic 1307, castor oil polyoxyethylene ether, Tween-20, Triton-100 and Brij-35.
优选地,R1试剂包括以下浓度的各成分:Preferably, the R1 reagent includes the following concentrations of each component:
缓冲液0.02-0.1M/L;Buffer 0.02-0.1M/L;
电解质20-40g/L;Electrolyte 20-40g/L;
促融剂30-80g/L;Melting agent 30-80g/L;
表面活性剂0.2-10g/L;Surfactant 0.2-10g/L;
防腐剂0.8-1.2g/L。Preservative 0.8-1.2g/L.
R2试剂包括以下浓度的各成分:The R2 reagent includes the following concentrations of each component:
抗脂联素单抗包被胶乳颗粒60-100mg/L;Anti-adiponectin monoclonal antibody coated latex particles 60-100mg/L;
缓冲液0.01-0.05M/L;Buffer 0.01-0.05M/L;
保护剂5-30g/L;Protective agent 5-30g/L;
稳定剂5-20g/L;Stabilizer 5-20g/L;
防腐剂0.8-1.2g/L;Preservative 0.8-1.2g/L;
表面活性剂0.2-10g/L。Surfactant 0.2-10g/L.
优选地,所述脂联素检测试剂盒中,所述表面活性剂包括Tetronic 1307和蓖麻油聚氧乙烯醚。Preferably, in the adiponectin detection kit, the surfactants include Tetronic 1307 and castor oil polyoxyethylene ether.
在R1中添加上述表面活性剂后,增强了试剂对特殊样本如脂浊类、溶血类样本的抗干扰能力,减小非特异性吸附的干扰;也避免样本测试过程中的假阴性和假阳性的出现,从而提升样本测试的准确性。Tetronic 1307和蓖麻油聚氧乙烯醚均为良好的增溶剂,能分散溶解油脂,可减少基质干扰和非特异性吸附,且二者均不破坏蛋白结构;尤其是蓖麻油聚氧乙烯醚,它的HLB值在13-14之间,具有有很好的去油污能力;此外,Tetronic 1307属于两性离子抗静电能力超强,可避免静电吸附导致的假阳性。The addition of the above surfactants to R1 enhances the anti-interference ability of the reagents to special samples such as lipid turbidity and hemolytic samples, reduces the interference of non-specific adsorption, and avoids false negatives and false positives during sample testing. appears, thereby improving the accuracy of sample testing. Both Tetronic 1307 and castor oil polyoxyethylene ether are good solubilizers, which can disperse and dissolve oils, reduce matrix interference and non-specific adsorption, and neither destroy the protein structure; especially castor oil polyoxyethylene ether, its The HLB value is between 13-14, which has a good degreasing ability; in addition, Tetronic 1307 is a zwitterion with super antistatic ability, which can avoid false positives caused by electrostatic adsorption.
在R2中加入Tetronic 1307和蓖麻油聚氧乙烯醚这两种表面活性剂,具有多种作用:一方面,可使胶乳试剂分散更均匀,增强胶乳试剂的重复性;另一方面,蓖麻油聚氧乙烯醚有优良的乳化能力,不仅能在蛋白表面形成水化膜,起到保护蛋白和增加蛋白稳定性的作用,还能形成表面张力,增强液体的稳定性。The addition of two surfactants, Tetronic 1307 and castor oil polyoxyethylene ether, into R2 has multiple effects: on the one hand, the latex reagent can be dispersed more uniformly and the repeatability of the latex reagent can be enhanced; on the other hand, castor oil polymerized Oxyethylene ether has excellent emulsifying ability. It can not only form a hydration film on the surface of the protein to protect the protein and increase the stability of the protein, but also form surface tension and enhance the stability of the liquid.
优选地,所述脂联素检测试剂盒中,所述保护剂选自海藻糖、蔗糖中的一种或两种。Preferably, in the adiponectin detection kit, the protective agent is selected from one or both of trehalose and sucrose.
优选地,所述脂联素检测试剂盒中,稳定剂选自酪蛋白和牛血清蛋白中的一种或几种。Preferably, in the adiponectin detection kit, the stabilizer is selected from one or more of casein and bovine serum albumin.
可选地,所述脂联素检测试剂盒中,所述缓冲液为TRIS缓冲液、磷酸盐缓冲液、HEPES缓冲液、柠檬酸缓冲液中的一种或几种。Optionally, in the adiponectin detection kit, the buffer is one or more of TRIS buffer, phosphate buffer, HEPES buffer, and citrate buffer.
可选地,所述电解质为氯化钠、氯化钾、氯化钙中的一种或几种。Optionally, the electrolyte is one or more of sodium chloride, potassium chloride, and calcium chloride.
可选地,所述促融剂为PEG6000、PEG8000、PEG12000中的一种或几种。Optionally, the fusogenic agent is one or more of PEG6000, PEG8000 and PEG12000.
可选地,所述防腐剂为叠氮钠、Proclin300中的一种或几种。Optionally, the preservative is one or more of sodium azide and Proclin300.
优选地,所述脂联素检测试剂盒中,R1试剂包括以下浓度的各组分:柠檬酸缓冲液0.02-0.1M/L;氯化钠20-40g/L;PEG6000 30-80g/L;Tetronic 13070.1-5g/L;蓖麻油聚氧乙烯醚0.1-5g/L;防腐剂0.8-1.2g/L;Preferably, in the adiponectin detection kit, the R1 reagent includes each component in the following concentrations: citrate buffer 0.02-0.1M/L; sodium chloride 20-40g/L; PEG6000 30-80g/L; Tetronic 13070.1-5g/L; castor oil polyoxyethylene ether 0.1-5g/L; preservative 0.8-1.2g/L;
R2试剂包括以下浓度的各组分:抗脂联素单抗包被胶乳颗粒:60-100mg/L;HEPES缓冲液0.01-0.1M/L;海藻糖5-30g/L;牛血清蛋白5-20g/L;Tetronic1307 0.1-5g/L;蓖麻油聚氧乙烯醚0.1-5g/L;防腐剂0.8-1.2g/L。The R2 reagent includes each component at the following concentrations: anti-adiponectin monoclonal antibody-coated latex particles: 60-100 mg/L; HEPES buffer 0.01-0.1 M/L; trehalose 5-30 g/L; bovine serum albumin 5- 20g/L; Tetronic1307 0.1-5g/L; Castor oil polyoxyethylene ether 0.1-5g/L; Preservative 0.8-1.2g/L.
可选地,R1试剂的PH值为6.0-7.4,R2试剂的PH值为7.0-7.8。优选地,R1试剂的PH值为7.0,R2试剂的PH值为7.4。Optionally, the pH of the R1 reagent is 6.0-7.4, and the pH of the R2 reagent is 7.0-7.8. Preferably, the pH of the R1 reagent is 7.0, and the pH of the R2 reagent is 7.4.
在此基础上,优选地,R1试剂的防腐剂采用0.8-1.2g/L的叠氮钠,R2试剂中的防腐剂采用0.8-1.2g/L的Proclin300。On this basis, preferably, 0.8-1.2 g/L sodium azide is used as the preservative of the R1 reagent, and 0.8-1.2 g/L Proclin300 is used as the preservative in the R2 reagent.
第二方面,本发明提供一种上述脂联素检测试剂盒的制备方法,其包括以下步骤:In a second aspect, the present invention provides a method for preparing the above-mentioned adiponectin detection kit, which comprises the following steps:
R1试剂的配制:按照试剂R1的组分含量,将缓冲液、电解质、促融剂、表面活性剂、防腐剂等依次分别溶于纯水中,搅拌均匀,调pH至6.0-7.4,搅拌均匀后置于35-40℃烘箱孵育一晚即得R1试剂;Preparation of Reagent R1: According to the component content of Reagent R1, dissolve buffer, electrolyte, melting agent, surfactant, preservative, etc. in pure water in turn, stir evenly, adjust pH to 6.0-7.4, and stir evenly After incubation at 35-40℃ for one night, the R1 reagent was obtained;
试剂R2的配制:向抗脂联素单抗包被胶乳颗粒中边搅拌边分别加入缓冲液、稳定剂和表面活性剂,最后加入防腐剂和保护剂,在35-40℃摇床稳定一夜后即得R2试剂。Preparation of reagent R2: Add buffer, stabilizer and surfactant to anti-adiponectin monoclonal antibody-coated latex particles while stirring, and finally add preservative and protective agent, and stabilize at 35-40°C on a shaker overnight. That is, the R2 reagent is obtained.
优选地,所述抗脂联素单抗包被胶乳颗粒的制备方法为:取粒径100-300nm的胶乳微球于MES缓冲液中,于35-40℃摇床,100-300r/min,摇匀3-10min;之后加入现配的EDC和NHS溶液,置于35-40℃摇床,100-300r/min,活化胶乳10-20min;在搅拌的情况下,加入缓冲液和抗体,置于35-40摇床,100-300r/min,偶联1-5h;所述抗体为抗脂联素单抗。Preferably, the preparation method of the anti-adiponectin monoclonal antibody-coated latex particles is as follows: take latex microspheres with a particle size of 100-300nm in MES buffer, shake at 35-40°C, 100-300r/min, Shake for 3-10min; then add the freshly prepared EDC and NHS solutions, place on a shaker at 35-40℃, 100-300r/min, activate the latex for 10-20min; under stirring, add buffer and antibody, set Shaking at 35-40, 100-300r/min, coupling for 1-5h; the antibody is anti-adiponectin monoclonal antibody.
优选地,在添加缓冲液、稳定剂和表面活性剂时,要在添加完前一种物质并于35-40℃摇床孵育20-40min后再加入后一种物质。Preferably, when adding buffers, stabilizers and surfactants, the latter substances should be added after adding the former substances and incubating at 35-40° C. for 20-40 min on a shaker.
优选地,所述抗脂联素单抗包被胶乳颗粒的制备方法为:所述抗脂联素单抗包被胶乳颗粒的制备方法为:取粒径为100-300nm的胶乳微球于MES缓冲液中,于35-40℃摇床,100-300r/min,摇匀3-10min;之后加入现配的EDC和NHS溶液,置于35-40℃摇床,100-300r/min,活化胶乳10-20min;在搅拌的情况下,加入缓冲液和抗体,置于35-40℃摇床,100-300r/min,偶联1-5h。Preferably, the preparation method of the anti-adiponectin monoclonal antibody-coated latex particles is as follows: the preparation method of the anti-adiponectin monoclonal antibody-coated latex particles is: taking latex microspheres with a particle size of 100-300 nm in MES In the buffer, shake at 35-40°C, 100-300r/min, shake for 3-10min; then add the freshly prepared EDC and NHS solutions, place on a shaker at 35-40°C, 100-300r/min, activate Latex for 10-20min; under stirring, add buffer and antibody, place on a shaker at 35-40°C, 100-300r/min, and couple for 1-5h.
进一步优选的条件为:取粒径100-300nm的胶乳微球于HEPES缓冲液中,置于37℃摇床,200r/min,活化胶乳15min;在搅拌的情况下,加入缓冲液和抗体,置于37℃摇床,200r/min,偶联3h。Further preferred conditions are as follows: take latex microspheres with a particle size of 100-300 nm in HEPES buffer, place on a shaker at 37 °C, 200 r/min, and activate the latex for 15 min; under stirring, add buffer and antibody, set to Shaking at 37°C, 200r/min, coupling for 3h.
优选地,HEPES缓冲液的浓度为0.01M-0.1M。Preferably, the concentration of HEPES buffer is 0.01M-0.1M.
优选地,所述脂联素检测试剂盒的制备方法包括以下步骤:Preferably, the preparation method of the adiponectin detection kit comprises the following steps:
试剂R1的配制:按照试剂R1的组分含量,将缓冲液、电解质、促融剂、表面活性剂、防腐剂等依次分别溶于纯水中,搅拌均匀,调pH至6.0-7.4,搅拌均匀后置于37℃烘箱孵育一晚即得试剂R1。Preparation of Reagent R1: According to the component content of Reagent R1, dissolve buffer, electrolyte, melt enhancer, surfactant, preservative, etc. in pure water in sequence, stir evenly, adjust pH to 6.0-7.4, and stir evenly After incubation at 37°C for one night, reagent R1 was obtained.
试剂R2的配制:取粒径为100-300nm的胶乳微球于0.01M-0.1M MES缓冲液中,置于37℃摇床,200r/min,摇匀5min;之后加入现配的EDC和NHS溶液,置于37℃摇床,200r/min,活化胶乳15min;在搅拌的情况下,加入HEPES缓冲液和抗体,置于37℃摇床,200r/min,偶联3h后从摇床中取出,置于搅拌器上,分别加入HEPES缓冲液、BSA和表面活性剂,上述物质均在加完一种物质于37℃摇床孵育30min后再加入另一种物质,最后加入防腐剂和保护剂,在37℃摇床稳定一夜后即得试剂R2。Preparation of reagent R2: Take latex microspheres with a particle size of 100-300nm in 0.01M-0.1M MES buffer, place on a shaker at 37°C, 200r/min, and shake for 5min; then add the freshly prepared EDC and NHS The solution was placed on a shaker at 37°C, 200 r/min, and the latex was activated for 15 minutes; under stirring, add HEPES buffer and antibody, placed on a shaker at 37°C, 200 r/min, and removed from the shaker after coupling for 3 hours. , placed on a stirrer, and added HEPES buffer, BSA and surfactant respectively. After adding one substance and incubating it on a shaker for 30 min at 37°C, add another substance, and finally add preservatives and protective agents. , and the reagent R2 was obtained after it was stabilized on a shaker at 37°C overnight.
第三方面,本发明还提供一种用于脂联素检测试剂盒的表面活性剂,其包括Tetronic 1307和蓖麻油聚氧乙烯醚。In a third aspect, the present invention also provides a surfactant for an adiponectin detection kit, which comprises Tetronic 1307 and castor oil polyoxyethylene ether.
可选地,Tetronic 1307的使用浓度为0.1-5g/L,蓖麻油聚氧乙烯醚的使用浓度为0.1-5g/L。Optionally, the use concentration of Tetronic 1307 is 0.1-5g/L, and the use concentration of castor oil polyoxyethylene ether is 0.1-5g/L.
本发明具有以下有益效果:The present invention has the following beneficial effects:
1、本发明采用新的表面活性剂组合与试剂盒中的其他成分配合,不仅增强了R1试剂对特殊样本如脂浊类和溶血类样本的抗干扰能力,减小非特异性吸附的干扰,避免样本测试过程中的假阴性和假阳性的出现,从而提升样本测试的准确性;还增强了胶乳试剂的重复性和稳定性。1. The present invention adopts a new combination of surfactants to cooperate with other components in the kit, which not only enhances the anti-interference ability of R1 reagent for special samples such as lipid turbidity and hemolytic samples, reduces the interference of non-specific adsorption, and avoids The occurrence of false negatives and false positives in the sample testing process improves the accuracy of sample testing; it also enhances the repeatability and stability of latex reagents.
2、该试剂盒完全避免了酶联免疫吸附和化学发光法的缺点,既可以快速的大批量的检测,又能进行单一样本的检测。相对于现有胶乳增强免疫比浊法制备的工艺复杂,耗费人力物力,本发明提供的脂联素检测试剂盒的制备工艺简单,无需离心和超声分散等步骤,节省时间的同时还有效降低了试剂的批间差。2. The kit completely avoids the shortcomings of enzyme-linked immunosorbent assay and chemiluminescence method, and can not only detect large batches quickly, but also detect a single sample. Compared with the existing latex-enhanced immune turbidimetric method, the preparation process is complex and consumes manpower and material resources. The preparation process of the adiponectin detection kit provided by the present invention is simple, and steps such as centrifugation and ultrasonic dispersion are not required, which saves time and effectively reduces the Lot-to-lot variation of reagents.
附图说明Description of drawings
图1本发明实施例1的校准曲线;Fig. 1 calibration curve of
图2本发明实施例1的线性范围。Figure 2 Linear range of Example 1 of the present invention.
具体实施方式Detailed ways
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。在本发明中,若非特指,所采用的设备和原料等均可从市场购得或是本领域常用的。下述实施例中的方法,如无特别说明,均为本领域的常规方法。The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, but not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative efforts shall fall within the protection scope of the present invention. In the present invention, unless otherwise specified, the equipment and raw materials used can be purchased from the market or commonly used in the field. The methods in the following examples, unless otherwise specified, are conventional methods in the art.
实施例1Example 1
本实施例提供一种抗干扰强、重复性好的脂联素检测试剂盒,其制备方法包括以下步骤:The present embodiment provides an adiponectin detection kit with strong anti-interference and good repeatability, the preparation method of which includes the following steps:
(1)试剂R1的配制:(1) Preparation of reagent R1:
称取100mL柠檬酸缓冲液,置于搅拌器上,按顺序依次加入3.0g NaCl、5gPEG6000、0.2g Tetronic 1307、0.1g蓖麻油聚氧乙烯醚、0.1g NaN3。一种物质完全溶解后再加入另一种物质,待完全溶解后调节pH至7.0,置37℃摇床孵育一晚后即为试剂R1。Weigh 100 mL of citric acid buffer, place it on a stirrer, and add 3.0 g of NaCl, 5 g of PEG6000, 0.2 g of Tetronic 1307, 0.1 g of castor oil polyoxyethylene ether, and 0.1 g of NaN3 in sequence. After one substance is completely dissolved, another substance is added. After complete dissolution, the pH is adjusted to 7.0, and the reagent R1 is obtained after incubating at 37°C for one night.
配置完成后,试剂R1各成分的浓度分别为:柠檬酸缓冲液50mM/L;氯化钠30g/L;PEG6000 50g/L;Tetronic 1307 2g/L;蓖麻油聚氧乙烯醚1g/L;NaN3 1g/L。After the configuration is completed, the concentrations of the components of reagent R1 are: citric acid buffer 50mM/L; sodium chloride 30g/L; PEG6000 50g/L; Tetronic 1307 2g/L; castor oil polyoxyethylene ether 1g/L; NaN3 1g/L.
(2)试剂R2的配制:(2) Preparation of reagent R2:
①抗脂联素单抗包被胶乳颗粒的制备:① Preparation of anti-adiponectin monoclonal antibody-coated latex particles:
取粒径为200nm的胶乳微球80ul于130ul的0.02M pH6.0的MES缓冲液中,置于37℃摇床,200r/min,摇匀2min。之后加入现配的EDC和NHS溶液中,置于37℃摇床,200r/min,摇匀15min以活化胶乳;EDC和NHS的浓度为0.10M,添加比例为1:1;之后,在搅拌的情况下,加入3ml HEPES缓冲液(0.02M pH7.4)和抗体溶液(单抗1和单抗2混合,其中单抗为鼠抗人ADP抗体),抗体添加总量为30mg/L。置于37℃摇床,200r/min,偶联3h。Take 80 ul of latex microspheres with a particle size of 200 nm in 130 ul of 0.02M MES buffer at pH 6.0, place on a shaker at 37°C, 200 r/min, and shake for 2 min. After that, it was added to the prepared EDC and NHS solution, placed on a shaker at 37°C, 200 r/min, and shaken for 15 minutes to activate the latex; the concentration of EDC and NHS was 0.10M, and the addition ratio was 1:1; In this case, add 3 ml of HEPES buffer (0.02M pH7.4) and antibody solution (mix of
②将上一步的混合物从摇床中取出,置于搅拌器上,分别加入1ml的HEPES缓冲液、500ul 10%的BSA,5ul Tetronic 1307、5ul蓖麻油聚氧乙烯醚。上述物质均在加完一种物质于37℃摇床孵育30min后再加入另一种物质,最后加入的5ul proclin300以及0.1g海藻糖,在37℃摇床孵育一夜后即得试剂R2。② Take the mixture from the previous step out of the shaker, place it on a stirrer, and add 1ml of HEPES buffer, 500ul of 10% BSA, 5ul of Tetronic 1307, and 5ul of castor oil polyoxyethylene ether, respectively. The above substances were all added after one substance was added and incubated at 37°C for 30 minutes before adding another substance. Finally, 5ul of proclin300 and 0.1g trehalose were added, and the reagent R2 was obtained after overnight incubation at 37°C.
制备完成后,试剂R2各成分的浓度分别为:抗脂联素单抗包被胶乳颗粒80mg/L、HEPES缓冲液25mM/L、BSA 10g/L、Tetronic 1307 1g/L、蓖麻油聚氧乙烯醚1g/L、proclin300 1g/L、海藻糖20g/L。After the preparation is completed, the concentrations of the components of reagent R2 are: anti-adiponectin monoclonal antibody-coated latex particles 80mg/L, HEPES buffer 25mM/L, BSA 10g/L, Tetronic 1307 1g/L, castor oil polyoxyethylene Ether 1g/L, proclin 300 1g/L, trehalose 20g/L.
实施例2Example 2
本实施例提供一种抗干扰强、重复性好的脂联素检测试剂盒,包括R1试剂和R2试剂,其制备方法,包括以下步骤:The present embodiment provides an adiponectin detection kit with strong anti-interference and good repeatability, including R1 reagent and R2 reagent, and the preparation method thereof includes the following steps:
(1)试剂R1的配制:(1) Preparation of reagent R1:
称取100ml柠檬酸缓冲液,置于搅拌器上,按顺序依次加入3.0g NaCl、5gPEG6000、0.2g Tetronic 1307、0.1g NaN3。一种物质完全溶解后再加入另一种物质,待完全溶解后调节pH至7.0,置37℃摇床孵育一晚后即为试剂R1。100 ml of citric acid buffer was weighed, placed on a stirrer, and 3.0 g of NaCl, 5 g of PEG6000, 0.2 g of Tetronic 1307, and 0.1 g of NaN 3 were added in sequence. After one substance is completely dissolved, another substance is added, and after complete dissolution, the pH is adjusted to 7.0, and the reagent R1 is obtained after incubating at 37°C in a shaker for one night.
配置完成后,试剂R1各成分的浓度分别为:柠檬酸缓冲液50mM/L;氯化钠30g/L;PEG6000 50g/L;Tetronic 1307 2g/L;NaN3 1g/L。After the configuration is completed, the concentrations of the components of reagent R1 are: citrate buffer 50mM/L; sodium chloride 30g/L; PEG6000 50g/L; Tetronic 1307 2g/L; NaN 3 1g/L.
(2)试剂R2的配制:(2) Preparation of reagent R2:
①抗脂联素单抗包被胶乳颗粒的制备:① Preparation of anti-adiponectin monoclonal antibody-coated latex particles:
取粒径为200nm的胶乳微球80ul于130ul 0.02M pH6.0的MES缓冲液中,置于37℃摇床,200r/min,摇匀2min。之后加入现配的EDC和NHS溶液中,置于37℃摇床,200r/min,摇匀15min以活化胶乳;EDC和NHS的浓度为0.10M,添加比例为1:1。之后在搅拌的情况下,加入3ml HEPES缓冲液(0.02M pH7.4)和抗体溶液(单抗1和2混合),抗体添加总量为30mg/L。置于37℃摇床,200r/min,偶联3h。Take 80 ul of latex microspheres with a particle size of 200 nm in 130 ul of 0.02M MES buffer at pH 6.0, place on a shaker at 37°C, 200 r/min, and shake for 2 min. Then, it was added to the prepared EDC and NHS solution, placed on a shaker at 37 °C, 200 r/min, and shaken for 15 min to activate the latex; the concentration of EDC and NHS was 0.10 M, and the addition ratio was 1:1. Then, under stirring, 3 ml of HEPES buffer (0.02M pH7.4) and antibody solution (mixing of
②将上一步的混合物从摇床中取出,置于搅拌器上,分别加入1ml的HEPES缓冲液、500ul 10%的BSA,5ul Tetronic 1307、5ul蓖麻油聚氧乙烯醚。上述物质均在加完一种物质于37℃摇床孵育30min后再加入另一种物质,最后加入的5ul proclin300以及0.1g海藻糖,在37℃摇床孵育一夜后即得试剂R2。② Take the mixture from the previous step out of the shaker, place it on a stirrer, and add 1ml of HEPES buffer, 500ul of 10% BSA, 5ul of Tetronic 1307, and 5ul of castor oil polyoxyethylene ether, respectively. The above substances were all added after one substance was added and incubated at 37°C for 30 minutes before adding another substance. Finally, 5ul of proclin300 and 0.1g trehalose were added, and the reagent R2 was obtained after overnight incubation at 37°C.
制备完成后,试剂R2各成分的浓度分别为:抗脂联素单抗包被胶乳颗粒80mg/L、HEPES缓冲液25mM/L、BSA 10g/L、Tetronic 1307 1g/L、蓖麻油聚氧乙烯醚1g/L、proclin300 1g/L、海藻糖20g/L。After the preparation is completed, the concentrations of the components of reagent R2 are: anti-adiponectin monoclonal antibody-coated latex particles 80mg/L, HEPES buffer 25mM/L, BSA 10g/L, Tetronic 1307 1g/L, castor oil polyoxyethylene Ether 1g/L, proclin 300 1g/L, trehalose 20g/L.
实施例3Example 3
本实施例提供一种脂联素检测试剂盒,包括R1试剂和R2试剂,其制备方法,包括以下步骤:This embodiment provides an adiponectin detection kit, including R1 reagent and R2 reagent, and a preparation method thereof includes the following steps:
(1)试剂R1的配制:(1) Preparation of reagent R1:
称取100mL柠檬酸缓冲液,置于搅拌器上,按顺序依次加入3.0g NaCl、5gPEG6000、0.1g蓖麻油聚氧乙烯醚、0.1g NaN3。一种物质完全溶解后再加入另一种物质,待完全溶解后调节pH至7.0,置37℃摇床孵育一晚后即为试剂R1。100 mL of citric acid buffer was weighed, placed on a stirrer, and 3.0 g of NaCl, 5 g of PEG6000, 0.1 g of castor oil polyoxyethylene ether, and 0.1 g of NaN 3 were added in sequence. After one substance is completely dissolved, another substance is added, and after complete dissolution, the pH is adjusted to 7.0, and the reagent R1 is obtained after incubating at 37°C in a shaker for one night.
配置完成后,试剂R1各成分的浓度分别为:柠檬酸缓冲液50mM/L;氯化钠30g/L;PEG6000 50g/L;蓖麻油聚氧乙烯醚1g/L;NaN3 1g/L。After the configuration is completed, the concentrations of the components of reagent R1 are: citric acid buffer 50mM/L; sodium chloride 30g/L; PEG6000 50g/L; castor oil polyoxyethylene ether 1g/L; NaN 3 1g/L.
(2)试剂R2的配制:(2) Preparation of reagent R2:
①抗脂联素单抗包被胶乳颗粒的制备:① Preparation of anti-adiponectin monoclonal antibody-coated latex particles:
取粒径为200nm的胶乳微球80ul于130ul 0.02M pH6.0的MES缓冲液中,置于37℃摇床,200r/min,摇匀2min。之后加入现配的EDC和NHS溶液中,置于37℃摇床,200r/min,摇匀15min以活化胶乳;EDC和NHS的浓度为0.10M,添加比例为1:1。之后在搅拌的情况下,加入3ml HEPES缓冲液(0.02M pH7.4)和抗体溶液(单抗1和2混合),抗体添加总量为30mg/L。置于37℃摇床,200r/min,偶联3h。Take 80 ul of latex microspheres with a particle size of 200 nm in 130 ul of 0.02M MES buffer at pH 6.0, place on a shaker at 37°C, 200 r/min, and shake for 2 min. Then, it was added to the prepared EDC and NHS solution, placed on a shaker at 37 °C, 200 r/min, and shaken for 15 min to activate the latex; the concentration of EDC and NHS was 0.10 M, and the addition ratio was 1:1. Then, under stirring, 3 ml of HEPES buffer (0.02M pH7.4) and antibody solution (mixing of
②将上一步的混合物从摇床中取出,置于搅拌器上,分别加入1ml的HEPES缓冲液、500ul 10%的BSA,5ul Tetronic 1307、5ul蓖麻油聚氧乙烯醚。上述物质均在加完一种物质于37℃摇床孵育30min后再加入另一种物质,最后加入的5ul proclin300以及0.1g海藻糖,在37℃摇床孵育一夜后即得试剂R2。② Take the mixture from the previous step out of the shaker, place it on a stirrer, and add 1ml of HEPES buffer, 500ul of 10% BSA, 5ul of Tetronic 1307, and 5ul of castor oil polyoxyethylene ether, respectively. The above substances were all added after one substance was added and incubated at 37°C for 30 minutes before adding another substance. Finally, 5ul of proclin300 and 0.1g trehalose were added, and the reagent R2 was obtained after overnight incubation at 37°C.
制备完成后,试剂R2各成分的浓度分别为:抗脂联素单抗包被胶乳颗粒80mg/L、HEPES缓冲液25mM/L、BSA 10g/L、Tetronic 1307 1g/L、蓖麻油聚氧乙烯醚1g/L、proclin300 1g/L、海藻糖20g/L。After the preparation is completed, the concentrations of the components of reagent R2 are: anti-adiponectin monoclonal antibody-coated latex particles 80mg/L, HEPES buffer 25mM/L, BSA 10g/L, Tetronic 1307 1g/L, castor oil polyoxyethylene Ether 1g/L, proclin 300 1g/L, trehalose 20g/L.
实施例4Example 4
本实施例提供一种抗干扰强、重复性好的脂联素检测试剂盒,包括R1试剂和R2试剂,其制备方法,包括以下步骤:The present embodiment provides an adiponectin detection kit with strong anti-interference and good repeatability, including R1 reagent and R2 reagent, and the preparation method thereof includes the following steps:
(1)试剂R1的配制:(1) Preparation of reagent R1:
称取100mL柠檬酸缓冲液,置于搅拌器上,按顺序依次加入3.0g NaCl、5gPEG6000、0.5g吐温-20、0.1g NaN3。一种物质完全溶解后再加入另一种物质,待完全溶解后调节pH至7.0,置37℃摇床孵育一晚后即为试剂R1。100 mL of citric acid buffer was weighed, placed on a stirrer, and 3.0 g of NaCl, 5 g of PEG6000, 0.5 g of Tween-20, and 0.1 g of NaN 3 were added in sequence. After one substance is completely dissolved, another substance is added, and after complete dissolution, the pH is adjusted to 7.0, and the reagent R1 is obtained after incubating at 37°C in a shaker for one night.
配置完成后,试剂R1各成分的浓度分别为:柠檬酸缓冲液50mM/L;氯化钠30g/L;PEG6000 50g/L;吐温-20 5g/L;NaN3 1g/L。After the configuration is completed, the concentrations of the components of the reagent R1 are: citric acid buffer 50mM/L; sodium chloride 30g/L; PEG6000 50g/L; Tween-20 5g/L; NaN 3 1g/L.
(2)试剂R2的配制:(2) Preparation of reagent R2:
①抗脂联素单抗包被胶乳颗粒的制备:① Preparation of anti-adiponectin monoclonal antibody-coated latex particles:
取粒径为200nm的胶乳微球80ul于130ul 0.02M pH6.0的MES缓冲液中,置于37℃摇床,200r/min,摇匀2min。之后加入现配的EDC和NHS溶液中,置于37℃摇床,200r/min,摇匀15min以活化胶乳;EDC和NHS的浓度为0.10M,添加比例为1:1。之后在搅拌的情况下,加入3ml HEPES缓冲液(0.02M pH7.4)和抗体溶液(单抗1和2混合),抗体添加总量为30mg/L。置于37℃摇床,200r/min,偶联3h。Take 80 ul of latex microspheres with a particle size of 200 nm in 130 ul of 0.02M MES buffer at pH 6.0, place on a shaker at 37°C, 200 r/min, and shake for 2 min. Then, it was added to the prepared EDC and NHS solution, placed on a shaker at 37 °C, 200 r/min, and shaken for 15 min to activate the latex; the concentration of EDC and NHS was 0.10 M, and the addition ratio was 1:1. Then, under stirring, 3 ml of HEPES buffer (0.02M pH7.4) and antibody solution (mixing of
②将上一步的混合物从摇床中取出,置于搅拌器上,分别加入1ml的HEPES缓冲液、500ul 10%的BSA,5ul Tetronic 1307、5ul蓖麻油聚氧乙烯醚。上述物质均在加完一种物质于37℃摇床孵育30min后再加入另一种物质,最后加入的5ul proclin300以及0.1g海藻糖,在37℃摇床孵育一夜后即得试剂R2。② Take the mixture from the previous step out of the shaker, place it on a stirrer, and add 1ml of HEPES buffer, 500ul of 10% BSA, 5ul of Tetronic 1307, and 5ul of castor oil polyoxyethylene ether, respectively. The above substances were all added after one substance was added and incubated at 37°C for 30 minutes before adding another substance. Finally, 5ul of proclin300 and 0.1g trehalose were added, and the reagent R2 was obtained after overnight incubation at 37°C.
制备完成后,试剂R2各成分的浓度分别为:抗脂联素单抗包被胶乳颗粒80mg/L、HEPES缓冲液25mM/L、BSA 10g/L、Tetronic 1307 1g/L、蓖麻油聚氧乙烯醚1g/L、proclin300 1g/L、海藻糖20g/L。After the preparation is completed, the concentrations of the components of reagent R2 are: anti-adiponectin monoclonal antibody-coated latex particles 80mg/L, HEPES buffer 25mM/L, BSA 10g/L, Tetronic 1307 1g/L, castor oil polyoxyethylene Ether 1g/L, proclin 300 1g/L, trehalose 20g/L.
实施例5Example 5
本实施例提供一种脂联素检测试剂盒,包括R1试剂和R2试剂,其制备方法,包括以下步骤:This embodiment provides an adiponectin detection kit, including R1 reagent and R2 reagent, and a preparation method thereof includes the following steps:
(1)试剂R1的配制:(1) Preparation of reagent R1:
称取100mL柠檬酸缓冲液,置于搅拌器上,按顺序依次加入3.0g NaCl、5gPEG6000、0.2g Tetronic 1307、0.1g蓖麻油聚氧乙烯醚、0.1g NaN3。一种物质完全溶解后再加入另一种物质,待完全溶解后调节pH至7.0,置37℃摇床孵育一晚后即为试剂R1。100 mL of citric acid buffer was weighed, placed on a stirrer, and 3.0 g of NaCl, 5 g of PEG6000, 0.2 g of Tetronic 1307, 0.1 g of castor oil polyoxyethylene ether, and 0.1 g of NaN 3 were added in sequence. After one substance is completely dissolved, another substance is added, and after complete dissolution, the pH is adjusted to 7.0, and the reagent R1 is obtained after incubating at 37°C in a shaker for one night.
配置完成后,试剂R1各成分的浓度分别为:柠檬酸缓冲液50mM/L;氯化钠30g/L;PEG6000 50g/L;Tetronic 1307 2g/L;蓖麻油聚氧乙烯醚1g/L;NaN3 1g/L。After the configuration is completed, the concentrations of the components of reagent R1 are: citric acid buffer 50mM/L; sodium chloride 30g/L; PEG6000 50g/L; Tetronic 1307 2g/L; castor oil polyoxyethylene ether 1g/L; NaN 31g /L.
(2)试剂R2的配制:(2) Preparation of reagent R2:
①抗脂联素单抗包被胶乳颗粒的制备:① Preparation of anti-adiponectin monoclonal antibody-coated latex particles:
取粒径为200nm的胶乳微球80ul于130ul 0.02M pH6.0的MES缓冲液中,置于37℃摇床,200r/min,摇匀2min。之后加入现配的EDC和NHS溶液中,置于37℃摇床,200r/min,摇匀15min以活化胶乳;EDC和NHS的浓度为0.10M,添加比例为1:1。之后在搅拌的情况下,加入3ml HEPES缓冲液(0.02M pH7.4)和抗体溶液(单抗1和2混合),抗体添加总量为30mg/L。置于37℃摇床,200r/min,偶联3h。Take 80 ul of latex microspheres with a particle size of 200 nm in 130 ul of 0.02M MES buffer at pH 6.0, place on a shaker at 37°C, 200 r/min, and shake for 2 min. Then, it was added to the prepared EDC and NHS solution, placed on a shaker at 37 °C, 200 r/min, and shaken for 15 min to activate the latex; the concentration of EDC and NHS was 0.10 M, and the addition ratio was 1:1. Then, under stirring, 3 ml of HEPES buffer (0.02M pH7.4) and antibody solution (mixing of
②将上一步的混合物从摇床中取出,置于搅拌器上,分别加入1ml的HEPES缓冲液、500ul 10%的BSA,10ul曲拉通-100。上述物质均在加完一种物质于37℃摇床孵育30min后再加入另一种物质,最后加入的5ul proclin300以及0.1g海藻糖,在37℃摇床孵育一夜后即得试剂R2。② Take the mixture from the previous step out of the shaker, place it on a stirrer, and add 1 ml of HEPES buffer, 500 ul of 10% BSA, and 10 ul of Triton-100, respectively. The above substances were all added after one substance was added and incubated at 37°C for 30 minutes before adding another substance. Finally, 5ul of proclin300 and 0.1g trehalose were added, and the reagent R2 was obtained after overnight incubation at 37°C.
制备完成后,试剂R2各成分的浓度分别为:抗脂联素单抗包被胶乳颗粒80mg/L、HEPES缓冲液25mM/L、BSA 10g/L、曲拉通-100 2g/L、proclin3001g/L、海藻糖20g/L。After the preparation is completed, the concentrations of the components of reagent R2 are: anti-adiponectin monoclonal antibody-coated latex particles 80mg/L, HEPES buffer 25mM/L, BSA 10g/L, Triton-100 2g/L, proclin3001g/L L, trehalose 20g/L.
实施例6脂联素检测试剂盒的应用Example 6 Application of adiponectin detection kit
本实施例的一种上述脂联素检测试剂盒的检测方法:A detection method of the above-mentioned adiponectin detection kit of the present embodiment:
1、生化分析仪检测1. Biochemical analyzer detection
以日立7180操作为例:测定波长为700nm,分别取不同浓度的校准品溶液(3uL),加入脂联素R1试剂(160uL),混匀,37℃孵育5分钟后,加入脂联素R2试剂(40uL),混匀,37℃孵育30秒后,读取各管吸光度值A1,反应4.5分钟后,读取各管吸光度值A2,计算吸光度差值△A=A2-A1,每管重复测定2次,以各校准管2次测得的吸光度差值△A的平均值为纵坐标,对应的校准品浓度为横坐标,绘制“浓度-吸光度差值”校准曲线。取待测血清或血浆样本,同法测定样本的吸光度差值,代入校准曲线,即可计算出待测样本中脂联素ADPN的含量。如果血清或血浆中脂联素的浓度超出校准曲线范围,需对样本进行稀释后再检测以保证检测结果的准确性。本试剂盒不仅适用于日立7180,还适用于其它品牌和型号的半自动、全自动生化分析仪,具体参数可根据仪器进行调整。Take the operation of Hitachi 7180 as an example: the measurement wavelength is 700nm, respectively take calibrator solutions (3uL) of different concentrations, add adiponectin R1 reagent (160uL), mix well, incubate at 37°C for 5 minutes, add adiponectin R2 reagent (40uL), mix well, incubate at 37°C for 30 seconds, read the absorbance value A1 of each tube, read the absorbance value A2 of each tube after 4.5 minutes of reaction, calculate the absorbance difference △A=A2-A1, repeat the measurement for each
实施例7试剂盒的质量评价Example 7 Quality evaluation of the kit
(1)标准曲线的制定(1) Establishment of standard curve
A、实验方法A. Experimental method
用蒸馏水倍比稀释高值校准品(42mg/L),浓度分别为:0mg/L,5.25mg/L,10.5mg/L,21mg/L,42mg/L。按照实施例6中的方法测定本发明脂联素校准品的标准曲线。实验对象为实施例1制备的脂联素检测试剂盒。Dilute the high-value calibrator (42mg/L) with distilled water, the concentrations are: 0mg/L, 5.25mg/L, 10.5mg/L, 21mg/L, 42mg/L. The standard curve of the adiponectin calibrator of the present invention was determined according to the method in Example 6. The experimental object is the adiponectin detection kit prepared in Example 1.
B、实验结果及分析B. Experimental results and analysis
如图1所示为本发明的实施例1的试剂盒的定标曲线。Figure 1 shows the calibration curve of the kit of Example 1 of the present invention.
(2)线性范围(2) Linear range
A、实验方法A. Experimental method
用接近线性范围上限的高浓度校准品(42mg/L)和接近线性范围下限的低浓度校准品品或蒸馏水,混合成至少5个稀释浓度(x)。分别测试试剂盒,每个稀释浓度测试2次,分别求出检测结果的均值(y)。以稀释浓度(x)为自变量,以检测结果均值(y)为因变量求出线性回归方程。实验对象为实施例1制备的脂联素检测试剂盒。Mix at least 5 dilution concentrations (x) with a high concentration calibrator (42 mg/L) near the upper limit of the linear range and a low concentration calibrator near the lower limit of the linear range or distilled water. The kits were tested separately, and each dilution concentration was tested twice, and the mean value (y) of the test results was obtained respectively. Taking the dilution concentration (x) as the independent variable and the mean value of the detection results (y) as the dependent variable, a linear regression equation was obtained. The experimental object is the adiponectin detection kit prepared in Example 1.
B、实验结果及分析B. Experimental results and analysis
如图2所示,本发明的试剂盒线性较好,回归方程为:y=0.9721x-0.0523,R2=0.9997。As shown in FIG. 2 , the kit of the present invention has good linearity, and the regression equation is: y=0.9721x-0.0523, R 2 =0.9997.
(3)分析灵敏度(3) Analytical Sensitivity
A、实验方法A. Experimental method
用实施例1制备的试剂盒测试已知浓度在10.5mg/L的校准品,记录在试剂盒规定参数下产生的吸光度变化值的绝对值,重复测试3次,取平均值并换算为10mg/L的吸光度变化值。Use the kit prepared in Example 1 to test the calibrator with a known concentration of 10.5 mg/L, record the absolute value of the absorbance change value generated under the specified parameters of the kit, repeat the test 3 times, take the average value and convert it to 10 mg/L The absorbance change value of L.
B、实验结果及分析B. Experimental results and analysis
测试结果分别为0.2504,0.2481,0.2492,换算为10mg/L的吸光度变化值为0.2373,这说明该试剂盒具有较高的灵敏度。The test results were 0.2504, 0.2481, and 0.2492, respectively, and the absorbance change value converted to 10 mg/L was 0.2373, which indicated that the kit had high sensitivity.
(4)重复性的检测(4) Repeated detection
A、实验方法A. Experimental method
用伊谱诺康公司测值为5.91mg/L的脂联素样本作为低值样本,按所述生化分析仪检测方法进行测定,各浓度分别重复测定10次,分别计算测定均值和标准差(S),以计算变异系数对实施例1和5的试剂盒进行重复性考察。The adiponectin sample with the measured value of 5.91 mg/L from Epinocon Company was used as the low-value sample, and the measurement was carried out according to the detection method of the biochemical analyzer. The measurement of each concentration was repeated 10 times, and the measurement mean and standard deviation were calculated respectively ( S), the reproducibility of the kits of Examples 1 and 5 was investigated by calculating the coefficient of variation.
由于试剂盒的重复性主要与R2试剂相关,因此该实验主要将实施例1和实施例5制备的试剂盒进行重复性考察。Since the reproducibility of the kit is mainly related to the R2 reagent, this experiment mainly examines the reproducibility of the kits prepared in Example 1 and Example 5.
B、实验结果及分析B. Experimental results and analysis
表1脂联素检测试剂盒的重复性测试结果Table 1 Repeatability test results of adiponectin detection kit
如表1的结果所示,实施例5中使用曲拉通-100作为表面活性剂后,试剂盒对低值样本的重复性不佳,达到7.13%,而实施例1加入新的表面活性剂组(Tetronic 1307和蓖麻油聚氧乙烯醚)后,试剂盒对低值样本的重复性明显改善,其变异系数低至2.02%。As shown in the results in Table 1, after Triton-100 was used as the surfactant in Example 5, the reproducibility of the kit for low-value samples was not good, reaching 7.13%, while the new surfactant was added in Example 1. Group (Tetronic 1307 and castor oil ethoxylate), the reproducibility of the kit for low-value samples was significantly improved, with a coefficient of variation as low as 2.02%.
(5)抗干扰实验(5) Anti-interference experiment
A、实验方法A. Experimental method
取浓度为5.91mg/L的脂联素样本,分别加入相同体积的不同浓度的干扰物质,使加入后的甘油三脂干扰物质的浓度分别为2.5g/L、5.0g/L、8.0g/L、胆红素的终浓度为400mg/L和血红蛋白的终浓度为10g/L,分别用实施例1-5制备的试剂盒对每个制备样本重复测定3次,取平均值,与加入相同体积蒸馏水的样本比较,观察加入干扰物质与加入蒸馏水后ADPN测定值的相对偏差。Take the adiponectin sample with a concentration of 5.91mg/L, and add the same volume of different concentrations of interfering substances respectively, so that the concentrations of the added triglyceride interfering substances are 2.5g/L, 5.0g/L, 8.0g/L, respectively. The final concentration of L and bilirubin was 400 mg/L and the final concentration of hemoglobin was 10 g/L. The test kits prepared in Examples 1-5 were used to measure each prepared sample 3 times, and the average value was taken, which was the same as adding Comparing the samples of volume distilled water, observe the relative deviation of ADPN determination value after adding interfering substances and adding distilled water.
B、实验结果及分析B. Experimental results and analysis
表2抗干扰实验结果Table 2 Anti-interference experimental results
注:相对偏差不超过±10%为基本达标。Note: The relative deviation does not exceed ±10% for the basic compliance.
从表2的实验结果可知,抗干扰能力由强到弱排序为:实施例1>实施例2>实施例3>实施例5>实施例4;其中,对于甘油三脂,实施例1-3的抗干扰能力基本达标;对于胆红素和血红蛋白干扰来说,实施例1-5的抗干扰能力基本达标。其中实施例1的试剂盒的抗干扰能力最优,加入不同浓度的干扰物质测定值与加入同体积蒸馏水后测定值相对偏差不超过4%。因此,当检测样本中存在一定浓度的干扰物质如甘油三酯,胆红素和血红蛋白,其对本发明试剂盒的测定结果无影响,本发明的抗干扰能力强。It can be seen from the experimental results in Table 2 that the anti-interference ability is ranked from strong to weak as follows: Example 1> Example 2> Example 3> Example 5> Example 4; wherein, for triglycerides, Examples 1-3 The anti-interference ability basically reaches the standard; for the interference of bilirubin and hemoglobin, the anti-interference ability of Examples 1-5 basically meets the standard. Among them, the anti-interference ability of the kit of Example 1 is the best, and the relative deviation of the measured value after adding different concentrations of interfering substances and adding the same volume of distilled water does not exceed 4%. Therefore, when a certain concentration of interfering substances such as triglyceride, bilirubin and hemoglobin exists in the detection sample, it has no effect on the measurement result of the kit of the present invention, and the present invention has strong anti-interference ability.
(5)稳定性(5) Stability
A、实验方法A. Experimental method
将本发明试剂盒置于37℃水浴中,分别在存放前(即未破坏时)、存放3天、5天、7天后对校准品进行定标并测试分装样本进行分析。The kit of the present invention was placed in a 37°C water bath, and the calibrators were calibrated before storage (ie, when not destroyed), after storage for 3 days, 5 days, and 7 days, and tested the subpackaged samples for analysis.
B、实验结果及分析B. Experimental results and analysis
从上表的结果可知,在37℃存放7天后,实施例1的试剂盒依然保持有99%以上的反应活性,这说明通过向试剂中添加Tetronic 1307和蓖麻油聚氧乙烯醚能显著提高该脂联素检测试剂盒在常温条件下的稳定性,增加了本发明试剂盒用于临床诊断的实用性。It can be seen from the results in the above table that after being stored at 37°C for 7 days, the kit of Example 1 still maintains a reactivity of more than 99%, which shows that adding Tetronic 1307 and castor oil polyoxyethylene ether to the reagent can significantly improve the reaction activity. The stability of the adiponectin detection kit under normal temperature conditions increases the practicability of the kit of the present invention for clinical diagnosis.
可以理解的是,对本领域普通技术人员来说,可以根据本发明的技术方案及本发明构思加以等同替换或改变,而所有这些改变或替换都应属于本发明所附的权利要求的保护范围。It can be understood that for those of ordinary skill in the art, equivalent replacements or changes can be made according to the technical solutions of the present invention and the inventive concept, and all these changes or replacements should belong to the protection scope of the appended claims of the present invention.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111655950.4A CN114295842B (en) | 2021-12-30 | 2021-12-30 | Adiponectin detection kit and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111655950.4A CN114295842B (en) | 2021-12-30 | 2021-12-30 | Adiponectin detection kit and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114295842A true CN114295842A (en) | 2022-04-08 |
CN114295842B CN114295842B (en) | 2025-02-14 |
Family
ID=80974150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111655950.4A Active CN114295842B (en) | 2021-12-30 | 2021-12-30 | Adiponectin detection kit and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114295842B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114295840A (en) * | 2021-12-29 | 2022-04-08 | 中元汇吉生物技术股份有限公司 | Kit for high-sensitivity quantitative determination of adiponectin and preparation method thereof |
CN115097141A (en) * | 2022-06-21 | 2022-09-23 | 广西康柏莱科技有限公司 | Adiponectin kit and preparation method thereof |
CN115902243A (en) * | 2022-10-31 | 2023-04-04 | 复星诊断科技(上海)有限公司 | A kind of adiponectin latex immunoturbidimetric assay kit and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104237522A (en) * | 2012-12-03 | 2014-12-24 | 武汉生之源生物科技有限公司 | Adiponectin content detection kit and preparation method thereof |
CN110274881A (en) * | 2018-03-14 | 2019-09-24 | 济南煊赫生物科技有限公司 | A kind of stabilization, total bilirubin (enzymatic measurement) detection reagent of strong antijamming capability and detection method |
US20200309770A1 (en) * | 2016-06-30 | 2020-10-01 | Shenzhen Yhlo Biotech Co., Ltd. | Chemiluminescence immunoassay kit for adiponectin, and preparation method and use thereof |
CN113156136A (en) * | 2021-02-05 | 2021-07-23 | 北京丹大生物技术有限公司 | Kit for detecting immunoglobulin G in urine |
CN113267635A (en) * | 2021-04-29 | 2021-08-17 | 广东优尼德生物科技有限公司 | Adiponectin antibody nano latex particle and kit for detecting adiponectin |
-
2021
- 2021-12-30 CN CN202111655950.4A patent/CN114295842B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104237522A (en) * | 2012-12-03 | 2014-12-24 | 武汉生之源生物科技有限公司 | Adiponectin content detection kit and preparation method thereof |
US20200309770A1 (en) * | 2016-06-30 | 2020-10-01 | Shenzhen Yhlo Biotech Co., Ltd. | Chemiluminescence immunoassay kit for adiponectin, and preparation method and use thereof |
CN110274881A (en) * | 2018-03-14 | 2019-09-24 | 济南煊赫生物科技有限公司 | A kind of stabilization, total bilirubin (enzymatic measurement) detection reagent of strong antijamming capability and detection method |
CN113156136A (en) * | 2021-02-05 | 2021-07-23 | 北京丹大生物技术有限公司 | Kit for detecting immunoglobulin G in urine |
CN113267635A (en) * | 2021-04-29 | 2021-08-17 | 广东优尼德生物科技有限公司 | Adiponectin antibody nano latex particle and kit for detecting adiponectin |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114295840A (en) * | 2021-12-29 | 2022-04-08 | 中元汇吉生物技术股份有限公司 | Kit for high-sensitivity quantitative determination of adiponectin and preparation method thereof |
CN115097141A (en) * | 2022-06-21 | 2022-09-23 | 广西康柏莱科技有限公司 | Adiponectin kit and preparation method thereof |
CN115097141B (en) * | 2022-06-21 | 2023-10-20 | 广西康柏莱科技有限公司 | Adiponectin kit and preparation method thereof |
CN115902243A (en) * | 2022-10-31 | 2023-04-04 | 复星诊断科技(上海)有限公司 | A kind of adiponectin latex immunoturbidimetric assay kit and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN114295842B (en) | 2025-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114295842A (en) | A kind of adiponectin detection kit and preparation method thereof | |
WO2018129885A1 (en) | Detection kit for whole blood c-reactive protein | |
CA1146852A (en) | Reagent for latex agglutination | |
Borque et al. | Development and validation of an automated and ultrasensitive immunoturbidimetric assay for C-reactive protein | |
CN111781362A (en) | Creatine kinase isoenzyme magnetic particle chemiluminescence detection kit and application thereof | |
CN101893619A (en) | Method for improving stability of latex suspension liquid | |
CN109444399A (en) | A kind of glycocholic acid detection kit | |
CN107607729A (en) | A kind of kit and preparation method of latex enhancing immune turbidimetry detection lipoprotein (a) | |
CN115327137B (en) | Human immunoglobulin G4 subtype chemiluminescence immunoassay kit | |
CN114594269B (en) | Serum amyloid A detection kit and preparation method thereof | |
CN112763731B (en) | Lipoprotein (a) determination kit and detection method thereof | |
CN115389761A (en) | Kit for measuring insulin by fluorescence immunochromatography and preparation method thereof | |
CN111337692B (en) | Adiponectin determination reagent and preparation method thereof | |
CN116466092B (en) | Kit for quantitatively determining uroretinol binding protein | |
CN110407934A (en) | Anti human albumin's mixed antibody and assay kit | |
CN115902243A (en) | A kind of adiponectin latex immunoturbidimetric assay kit and preparation method thereof | |
CN116626278A (en) | Method for improving linear range of latex enhanced turbidimetry kit and latex enhanced turbidimetry kit | |
CN108918888A (en) | It is a kind of detect Endostatin latex enhancing immune than turbid kit and its application | |
CN114112957B (en) | Adiponectin determination kit and application thereof | |
CN114924084A (en) | A glycosylated hemoglobin assay kit, preparation method and application thereof | |
CN114076741A (en) | Preparation method of glycocholic acid detection kit | |
CN112198319A (en) | Human immunoglobulin G4 kit with enhanced stability | |
CN118091149A (en) | Immunobuy kit for determining C-reactive protein | |
WO2020085417A1 (en) | Liquid diluent for measurement samples | |
CN117092353A (en) | Immunoglobulin G4 detection kit and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |